Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Status:
Completed
Trial end date:
2018-11-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find how good and how safe the combination of irinotecan,
temozolomide and bevacizumab is for patients with resistant or recurrent neuroblastoma. These
drugs have each been given separately to patients, but they have never been given all
together. Irinotecan and temozolomide are two drugs that have been used together to treat
neuroblastoma in many people. These drugs are considered chemotherapy. Bevacizumab is another
drug used to treat cancer. It is made by a company called Genentech. Bevacizumab is an
antibody. Antibodies are proteins that are found in the blood and can attach themselves to
bacteria and viruses. Bevacizumab attaches itself to a special protein in the bloodstream.
This protein helps tumors grow new blood vessels. Blood vessels carry nutrients to feed the
tumor. Bevacizumab is thought to block this growth of new blood vessels and starve tumors. It
has been used for the treatment of many cancers in adults. It is approved by the FDA for the
treatment of adults with colon cancer and other cancers but not for people with
neuroblastoma. There is only a small amount of information known on using this drug in
children. It has been used with irinotecan before to treat cancer but not in children with
neuroblastoma.